| CYTOMX THERAPEUTICS INC. |
| USA |
| Gesundheit |
| US23284F1057 / A14158 |
| 6C1 (Frankfurt) / CTMX (NASDAQ) |
| FRA:6C1, ETR:6C1, 6C1:GR, NASDAQ:CTMX |
| - |
| https://cytomx.com/ |
|
CytomX Therapeutics Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. The company's proprietary PROBODY® therapeutic platfo..
>Volltext.. |
| 645.9 Mio. EUR |
| 348.2 Mio. EUR |
| 30.57 Mio. EUR |
| -54.62 Mio. EUR |
| -50.86 Mio. EUR |
| -0.31 EUR |
| 2.46 Mio. EUR |
| 24.79 Mio. EUR |
| - |
| 10.19 |
| -77.45% |
| -233.11% |
| - |
| - |
| - |
| - |
| CYTOMX |
| 03.06.26 |